Innovus Pharmaceuticals (OTCMKTS:INNV) posted its quarterly earnings results on Tuesday. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.47), Morningstar.com reports. The company had revenue of $6.85 million during the quarter, compared to analyst estimates of $7.65 million. Innovus Pharmaceuticals had a negative return on equity of 1,053.29% and a negative net margin of 34.02%.
Shares of Innovus Pharmaceuticals stock traded down $0.28 during trading hours on Wednesday, reaching $1.50. The company’s stock had a trading volume of 6,617 shares, compared to its average volume of 6,799. Innovus Pharmaceuticals has a one year low of $1.05 and a one year high of $17.33. The stock has a market cap of $4.38 million, a P/E ratio of -0.36 and a beta of 2.22. The business has a fifty day simple moving average of $1.56. The company has a quick ratio of 0.50, a current ratio of 0.80 and a debt-to-equity ratio of 0.64.
INNV has been the subject of a number of research reports. ValuEngine upgraded shares of Innovus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. HC Wainwright initiated coverage on shares of Innovus Pharmaceuticals in a report on Tuesday, May 21st. They issued a “buy” rating for the company.
Innovus Pharmaceuticals, Inc, a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality.
Receive News & Ratings for Innovus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.